Erratum: AKT inhibitors promote cell death in cervical cancer through disruption of mtor signaling and glucose uptake (PLoS ONE (2014) 9(4): e92948. doi:10.1371/journal.pone.0092948);AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Rashmi, Ramachandran ^a   DeSelm, Carl ^a   Helms, Cynthia ^a   Bowcock, Anne ^a   Rogers, Buck E ^a,c   Rader, Janet ^d   Grigsby, Perry W ^a,b,c   Schwarz, Julie K ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; DEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; SC 66; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLOHEXANONE DERIVATIVE; FUSED HETEROCYCLIC RINGS; GLUCOSE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; SC-66 COMPOUND; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CANCER CELL; CELL DEATH; CELL DISRUPTION; CELL MEMBRANE; CELL MIGRATION; CELL VIABILITY; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE MUTATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PIK3CA GENE; PROSPECTIVE STUDY; PTEN GENE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR BIOPSY; UTERINE CERVIX CANCER; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CYCLOHEXANONES; FEMALE; GLUCOSE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; UTERINE CERVICAL NEOPLASMS;

EID: 84899414047     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107846     Document Type: Erratum

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Grigsby PW, Siegel BA, Dehdashti F (2001) Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 19: 3745-3749. (Pubitemid 32844787)
3. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW (2007) Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 298: 2289-2295. (Pubitemid 350146219)
4. Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D (2009) The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med 50 Suppl 1: 64S-73S.
5. Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, et al. (2012) Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res 18: 1464-1471.
6. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
7. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644.
8. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, et al. (2008) Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 3: e3065.
9. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, et al. (2008) NVPBEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030.
10. MacConaill LE, Campbell CD,Kehoe SM, Bass AJ,Hatton C, et al. (2009) Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4: e7887.
11. Kaplan EL, Meier P (1958) Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association 53: 457-481.
12. Pang H, Flinn R, Patsialou A, Wyckoff J, Roussos ET, et al. (2009) Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res 69: 8868-8876.
13. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, et al. (2007) The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318: 1744-1748. (Pubitemid 350274378)
14. Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, et al. (2008) PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation. Cancer Res 68: 8127-8136.
15. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, et al. (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65: 10992-11000. (Pubitemid 41713369)
16. Han SY, Kato H, Kato S, Suzuki T, Shibata H, et al. (2000) Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 60: 3147-3151. (Pubitemid 30407908)
17. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, et al. (1999) Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99: 323-334. (Pubitemid 29519911)
18. Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, et al. (2007) Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109: 3509-3512.
19. Proud CG (2009) mTORC1 signalling and mRNA translation. Biochem Soc Trans 37: 227-231.
20. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, et al. (2006) A negative feedback signaling network underlies oncogeneinduced senescence. Cancer Cell 10: 459-472. (Pubitemid 44872980)
21. Larue L, Bellacosa A (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24: 7443-7454. (Pubitemid 41637984)
22. Cui B, Zheng B, Zhang X, Stendahl U, Andersson S, et al. (2009) Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. Int J Oncol 34: 409-416.
23. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, et al. (2011) mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1: 248-259.
24. Yang J, Cron P, Thompson V, Good VM, Hess D, et al. (2002) Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell 9: 1227-1240. (Pubitemid 34722302)
25. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, et al. (1997) 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 7: 776-789. (Pubitemid 27441832)
26. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, et al. (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15: 148-159.
27. Currie RA, Walker KS, Gray A, Deak M, Casamayor A, et al. (1999) Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 337 (Pt 3): 575-583.
28. Majumder PK, Sellers WR (2005) Akt-regulated pathways in prostate cancer. Oncogene 24: 7465-7474. (Pubitemid 41637986)
29. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274. (Pubitemid 46962095)
30. Gonzalez E, McGraw TE (2009) The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 8: 2502-2508.
31. Wofford JA, Wieman HL, Jacobs SR, Zhao Y, Rathmell JC (2008) IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood 111: 2101-2111. (Pubitemid 351451522)
32. Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ (2000) Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Ann N Y Acad Sci 899: 349-362. (Pubitemid 30352799)
33. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR (2007) 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 67: 3364-3370. (Pubitemid 46724876)
34. McIntyre JB, Wu JS, Craighead PS, Phan T, Kobel M, et al. (2013) PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol 128: 409-414.